Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acelrx, Advanz, Akebia, Amarin, Armas, Brainstorm, Correvio, Homology, Kirin, Medivir, Nanoviricides, Pharmamar, Protalix, Spherix, Tango, Tetraphase, Therapeuticsmd, Twist, Xortx.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: AGTC, Aimmune, Aptevo, Arcutis, Biocryst, Can-Fite, Genetx, Moderna, Novo Nordisk, Regeneron, Sanofi.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bausch Health, Bioreference Laboratories, Cherrycircle Software, Co-Diagnostics, Evisit, Luminex, Medable, MIP Diagnostics, National Kidney Foundation, Opko, Precheck Health Services, Qiagen, Science37, Veravas, Vitalhub.
Mallinckrodt plc is engaging with the U.S. FDA, NIH and the Biomedical Advanced Research and Development Authority to address the potential use of its INOmax (nitric oxide) inhaled gas to treat COVID-19-associated lung complications. INOmax is marketed in the U.S. by the Staines-upon-Thames, U.K.-based company to treat full- and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension.
Another volatile day of trading in health care stocks unfolded March 13, after a trebling of broader market carnage the day before and the declaration of a national emergency by U.S. President Donald Trump Friday afternoon. Substantial declines hit shares of Moderna Inc., Vaxart Inc. and Inovio Pharmaceuticals Inc., all of which had recently rallied on optimism over coronavirus-fighting efforts. Biopharma shares saw some recovery, with both the S&P 500 Health Care Sector and Nasdaq biotechnology indices each rising a bit more than 2% each before Friday's close.